CCR8-depleting antibodies restore response to radiotherapy plus anti-PD1 therapy in head and neck cancer by targeting intratumoral CCR8+ regulatory T cells
Previous evidence has implicated regulatory T cells (Tregs) in treatment resistance in head and neck cancer.